Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 8/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26124399 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL23248470 | 0.94 | P2RX7 (0.33) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL26122403 | 0.92 | P2RX7 (0.34) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL30555465 | 0.92 | P2RX7 (0.34) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL30555510 | 0.87 | KDM4C (0.39) | CYP11B1CYP11B2P2RX7LRRK2RORC | |
| SCHEMBL23248496 | 0.87 | KDM4C (0.39) | CYP11B1CYP11B2P2RX7LRRK2RORC | |
| SCHEMBL30555512 | 0.86 | PTK6 (0.33) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL26121314 | 0.86 | PTK6 (0.33) | CYP11B1CYP11B2P2RX7PTK6LRRK2 | |
| SCHEMBL30555527 | 0.85 | SYK (0.34) | P2RX7KDM4C | |
| SCHEMBL26122222 | 0.85 | SYK (0.34) | P2RX7KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | CYP11B1 1979/4885CYP11B2 2508/4885P2RX7 3873/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | CYP11B1 1979/4885CYP11B2 2508/4885P2RX7 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.